StockVS

American Shared Hospital Services (AMS) 股票分析

医疗保健

American Shared Hospital Services

$1.35

+$0.00 (+0.00%)

最后更新: 2026年5月26日

价格走势

分析

公司概述

American Shared Hospital Services operates within the healthcare sector, specifically focusing on the medical care facilities industry by providing specialized technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. The company functions through two distinct segments, Leasing and Retail, offering nine Gamma Knife systems and one proton beam radiation therapy system to its client base. As of the latest data, the company possesses a market capitalization of $8.78 million and generates annual revenue totaling $28.08 million, while its employee count is not publicly disclosed. These valuation and revenue figures indicate that American Shared Hospital Services functions as a micro-cap entity with a relatively small market footprint, positioning it as a niche player rather than a large-scale diversified healthcare provider.

财务健康

The company reported a trailing twelve-month revenue of $28.08 million against a net income of -$1,553,000, revealing a significant gap that highlights substantial cost structures and operational inefficiencies eating into gross profits. Despite generating an EBITDA of $3.70 million, the entity is currently producing negative free cash flow of -$3,995,500, which suggests limited financial flexibility and an inability to convert earnings into liquid cash reserves for immediate reinvestment. The gross margin stands at 38.3%, indicating a healthy markup on sales before operating expenses, yet the operating margin has contracted to -14.0% and the profit margin to -5.5%, signaling that overhead costs and other operational expenses are exceeding operating earnings. On the balance sheet, the company holds $3.46 million in cash while carrying $21.67 million in debt, resulting in a debt-to-equity ratio of 78.27, which characterizes a highly leveraged financial structure reliant on external financing. The current ratio of 0.76 further underscores potential short-term liquidity challenges, as current assets are insufficient to cover current liabilities without external funding or asset sales. Additionally, the return on equity is -9.4% and the return on assets is -2.2%, metrics that collectively reveal that management has not been effective in generating profitable returns on the capital invested in the business during the reporting period.

估值评估

Valuation metrics present a complex picture with a trailing P/E ratio marked as N/A due to negative earnings, contrasted sharply by a forward P/E of 3.33, which implies market expectations of a future earnings turnaround or a re-rating of profitability. The price-to-book ratio is 0.36, indicating that the stock trades at a significant discount to its book value, suggesting the market prices in substantial operational risks or asset impairment concerns. Alternative valuation measures such as a price-to-sales ratio of 0.31 and an EV/EBITDA of 8.28 provide context, showing the company trades at less than one-third of its sales revenue and offers a low multiple on enterprise value relative to earnings before interest, taxes, depreciation, and amortization. Regarding trading range, the stock has fluctuated between a 52-week high of $3.11 and a 52-week low of $1.29, meaning the current valuation sits within a compressed band reflecting recent market volatility. The beta of 0.29 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it behaves more like a defensive or low-volatility asset despite its underlying financial stress.

Growth & Income

Revenue growth year-over-year has declined by 14.8%, while earnings growth is not applicable given the current losses, indicating that the company is contracting in terms of top-line sales without any immediate earnings recovery. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings and cash flow to address its debt obligations and fund operations rather than distributing income to shareholders. The absence of a dividend program reflects the company's current priority on capital preservation and solvency management rather than income generation for investors. Overall, the growth and income profile is characterized by negative revenue momentum, a complete lack of dividend income, and a financial structure that requires strict cost management to achieve future profitability.

同行比较

American Shared Hospital Services (AMS) 在医疗保健设施行业运营。以下是其与市值最接近的同行的比较:

公司 代码 市值 市盈率
American Shared Hospital Services AMS $8.94M N/A
HCA Healthcare, Inc. HCA $87.05B 13.5
Tenet Healthcare Corporation THC $15.19B 9.2
DaVita Inc. DVA $12.55B 18.8

医疗保健设施行业平均市盈率为28.6倍。American Shared Hospital Services的市盈率为N/A。

本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。

关于American Shared Hospital Services

American Shared Hospital Services provides technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. It operates in two segments: Leasing and Direct Patient Service. The company leases nine Gamma Knife systems and one proton beam radiation therapy (PBRT) system; and provides planning, installation, reimbursement, and marketing support services. It also owns and operates two single-unit Gamma Knife facilities that provides radiosurgery services directly to the patient. The company markets its solutions to cancer treatment centers, health systems, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.

公司简介以英文显示。

访问官网 →

关键指标

市值
$8.94M
市盈率
N/A
52周最高
$3.11
52周最低
$1.25
平均成交量
169.59K
Beta系数
0.32

数据由Yahoo Finance通过yfinance提供。每日更新。

公司信息

交易所
AMEX
国家
United States
员工数
82